Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium

Histopathology

Volumn 33, Issue 4, 1998, Pages 297-303

  Burton, J L ^a   Wells, M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cancer; Endometrium; Molecular pathology

Indexed keywords

ESTROGEN RECEPTOR; MICROSATELLITE DNA; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; VASCULOTROPIN;

CLEAR CELL CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADENOCARCINOMA; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTADENOCARCINOMA, PAPILLARY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, STEROID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031793789     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00560.x     Document Type: Review

References (64)

1. Rose PG. Endometrial circinoma. N. Engl. J. Med. 1996; 335: 640-649.
2. Hoffman K, Nekhlyudar L, Deligclisch L. Endometrial carcinoma in elderly women. Gynecol. Oncol. 1995: 58; 198-201.
3. dos Santos Silva I, Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br. J. Cancer 1995: 72; 485-192.
4. Zaino RJ. Taking another look at endometrial adenocarcinoma. Int. J. Gynecol. Pathol. 1996: 15; 187-190.
5. Sividris E, Fox H, Buckley CH. Endometrial carcinoma: two or three entities? Int. J. Gynecol. Cancer 1998: 8; 183-188.
6. Tritz D, Pieretti M, Turner S, Powell D. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum. Pathol. 1997: 28; 607-612.
7. Longacre TA, Kempson RL, Hendrickson MR. Endometrial hyperplasia, metaplasia and carcinoma. In Fox H, Wells M, eds. Obstetrical and Gynaecological Pathology, 4th edn. Edinburgh: Churchill Livingstone, 1995: 421-510.
8. Deligdisch L, Cohen CJ. Histologic correlation and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985; 56; 1452-1455.
9. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumours displaying serous differentiation. Hum. Pathol. 1995: 26; 1260-1267.
10. Kaku T, Silverberg SG, Tsukamoto N et al. Association of endometrial epithelial metaplasias with endometrial carcinoma and hyperplasia in Japanese and American women. Int. J. Gynecol. Pathol. 1993: 12; 297-300.
11. Parkash V, Carcangiu ML. Endometrioid endometrial adenocarcinoma with psammoma bodies. Am. J. Surg. Pathol. 1997: 21; 599-406.
12. Yamamoto R, Ishikura H, Azuma M et al. Alpha-fetoprotein production by a hepatoid adenocarcinoma of the uterus. J. Clin. Pathol. 1996: 49; 4250-422.
13. Hoshida Y, Nagakawa T, Mano S, Taguchi K, Aozasa K. Hepatoid adenocarcinoma of the endometrium associated with alpha-fetoprotein production. Int. J. Gynecol. Pathol. 1996: 15; 266-269.
14. Eichorn JH, Young RH, Clement PB. Sertoliform endometrial adenocarcinoma: a study of four cases. Int. J. Gynecol. Pathol. 1996: 15; 119-126.
15. Gitsch G, Friedlander ML, Wain GV, Hacher NF. Uterine papillary serous carcinoma: a clinical study. Cancer 1995: 75; 2239-2243.
16. Silverberg SG, Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease. Atlas of Tumour Pathology, 3rd series, fascicle 3, 1991; 47-89.
17. Carcangiu ML, Tan LK, Chambers JT. Stage 1A uterine serous carcinoma: a study of 13 cases. Am. J. Surg. Pathol. 1997: 21; 1507-1514.
18. Demopoulos RI, Genega E, Vamvakas E, Carlson E, Mittal K. Papillary carcinoma of the endometrium: morphometric predictors of survived. Int. J. Gynecol. Pathol. 1996: 15; 110-118.
19. Tashiro H, Lax SF, Gaudin PB, Isacson C, Cho KR, Hedrick L. Microsatellite instability is uncommon in uterine serous carcinoma. Am. J. Pathol. 1997: 150; 75-79.
20. Malpica A, Tornos C, Burke TW, Silva EG. Low stage clear-cell carcinoma of the endometrium. Am. J. Surg. Pathol. 1995: 19; 769-774.
21. Zheng W, Yang GCH, Godwin TA, Caputo TA, Zuna RE. Mucinous adenocarcinoma of the endometrium with intestinal differentiation: a case report. Hum. Pathol. 1995: 26; 1382-1388.
22. Zaloudek C, Hayashi GM, Ryan IP, Powell CB, Miller TR. Microglandular adenocarcinoma of the endometrium: a form of mucinous adenocarcinoma that may be confused with microglandular hyperplasia of the cervix. Int. J. Gynecol. Pathol. 1997: 16; 52-59.
23. Esteller M, Garcia A, Martinez-Paolones JM, Xercavins J, Reventós J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYPIAI) loci. Br. J. Cancer 1997: 75; 1385-1388.
24. Porter PL, Gown AM, Kramp SG, Coltrera MD, Widespread p53 overexpression in human malignant tumours: an immunohistochemical sludy using methacarn-fixed, embedded tissue. Am. J. Pathol. 1992: 140; 145-153.
25. Kohler MF, Carney P, Dodge R et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am. J. Obstet. Gynecol. 1996: 175; 1246-1252.
26. Stewart RL, Royds JA, Burton JL, Heatley MK, Wells M. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology (in press).
27. Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am. J. Pathol. 1996: 148; 1671-1678.
28. Kohlberger P, Gitsch G, Loesch A et al. p53 protein overexpression in early stage endometrial cancer. Gynecol. Oncol. 1996: 62; 213-217.
29. Ito K, Watanabe K, Nasim S et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res. 1994: 54; 4667-4670.
30. Inoue M, Fujita M, Enomoto T et al. Immunohistochemmical analysis of p53 in gynecologic: tumors. Am. J. Clin. Pathol. 1994: 102; 665-670.
31. Manek S, Wells M. The significance of alterations in p53 expression in gynaecological neoplasms. Curr. Opin. Obstet. Gynecol. 1996: 8; 52-55.
32. Battifora H. p53 immunohistochemistry: a word of caution. Hum. Pathol. 1994: 25; 435-437.
33. Save V, Sylander K, Hall PA. Why is p53 protein stabilized in neoplasia? Some answers but many more questions! J. Pathol. 1998: 184; 348-350.
34. Jones MW, Kounelis S, Hsu C et al. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathological and molecular comparison. Int. J. Gynecol. Pathol. 1997: 16; 354-360.
35. Taskin M, Lallas TA, Shevchuk M, Barber HRK. p53 expression in adenomyosis in endometrial carcinoma patients. Gynecol. Oncol. 1996: 62; 241-246.
36. Kohler MF, Nishii H, Humphrey PA et al. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. Am. J. Obstet. Gynecol. 1993: 169; 690-694.
37. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum. Pathol. 1995: 26; 1268-1274.
38. Yu CC-W, Wilkinson N, Brito MJ, Buckley CH, Fox H, Levison DA. Patterns of immunohistochemical staining for proliferating cell nuclear antigen and p53 in benign and neoplastic human endometrium. Histopathology 1993: 23; 367-371.
39. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC Jr The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol. 1994: 170; 246-252.
40. Nielson AL, Nyholm HCJ. p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. Am. J. Clin. Pathol. 1994: 102; 76-79.
41. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrial subtypes. Gynecol. Oncol. 1996: 61; 167-174.
42. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br. J. Cancer 1996: 74; 562-567.
43. Ito K, Sasano H, Matsunaga G et al. Correlations between p21 expression and clinicopathological findings. p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J. Pathol. 1997: 183; 318-324.
44. Tashiro H, Isacson I, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 1997: 150; 177-185.
45. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int. J. Gynecol. Pathol. 1996: 15; 202-208.
46. Shiozawa T, Xin L, Nikaido T, Fulii S. Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas. Int. J. Gynecol. Pathol. 1997: 16; 348-353.
47. Taskin M, Lallas TA, Barber HRK, Shevchuk MM. bcl-2 and p53 in endometrial adenocarcinoma. Mod. Pathol. 1997: 10; 728-734.
48. Backe J, Gassel AM, Hauber K et al. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int. J. Gynecol. Pathol. 1997: 16; 361-368.
49. Nagase S, Sato S, Tezuka F, Wada Y, Yajima A, Horii A. Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. Br. J. Cancer 1996: 74; 1979-83.
50. Suzuki A, Fukushige S, Nagase S, Ohuchi N, Satomi S, Horii A. Frequent gains on chromosome arms 1q and/or 8q in human endometrial cancer. Hum. Genet. 1997: 100; 629-636.
51. Evans MP, Podratz KC. Endometrial neoplasia: prognostic significance of ploidy status. Clin. Obstet. Gynecol. 1996: 39; 696-706.
52. Koreth J, O'Leary JJ, McGee J. O'D. Microsatellites and PCR genomic analysis. J. Pathol. 1996: 178; 239-248.
53. Burks RT, Kessis TD, Cho KR, Hedrick L. Microsatellite instability in endometrial carcinoma. Oncogen 1994: 9; 1163-1166.
54. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997: 57; 4736-4738.
55. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HY, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res. 1993: 53; 5100-5103.
56. Jeyarajah A, Oram D, Jacobs I. Molecular events in endometrial carcinogenesis. Int J. Gynecol. Cancer 1996: 6; 425-438.
57. Katabuchi H, van Rees B, Lambers AR et al. Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res. 1995: 55; 5556-5560.
58. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993: 71; 1467-1470.
59. Zhang L, Scott PAE, Turley H et al. Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localisation of VEGF in tissue sections: expression of VEGF in the human endometrium. J. Pathol. 1998: 185; 402-408.
60. Matthews RP, Hutchinson-Colas J, Maiman M et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in Black Women. Gynecol. Oncol. 1997: 65; 206-212.
61. Nordström B, Strang P, Lindgren A, Bergström R, Tribukait B. Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? Int. Gynecol. Pathol. 1996: 15; 191-201.
62. Takeshima N, Hirai Y, Tanaka N, Yamawaki T, Yamauchi K, Hasumi K. Pelvic lymph node metastases in endometrial cancer with no myometrial invasion. Obstet. Gynecol. 1996: 88; 280-282.
63. Inoue Y, Obata K, Abe K, et al. The prognostic significance of vascular invasion by endometrial carcinoma. Cancer 1996: 78; 1447-1451.
64. Kaku T, Kamura T, Kinukawa N et al. Angiogenesis in endometrial carcinoma. Cancer 1997: 80; 741-747.